National Coverage Determination (NCD)

Transtelephonic Monitoring of Cardiac Pacemakers

20.8.1.1

Expand All | Collapse All

Tracking Information

Publication Number
100-3
Manual Section Number
20.8.1.1
Manual Section Title
Transtelephonic Monitoring of Cardiac Pacemakers
Version Number
1
Effective Date of this Version
10/03/2003
Ending Effective Date of this Version
Implementation Date
Implementation QR Modifier Date

Description Information

Benefit Category
Outpatient Hospital Services Incident to a Physician's Service


Please Note: This may not be an exhaustive list of all applicable Medicare benefit categories for this item or service.

Item/Service Description

A. General

Transtelephonic monitoring of pacemakers is furnished by commercial suppliers, hospital outpatient departments, and physicians’ offices.

Telephone monitoring of cardiac pacemakers as described below is medically efficacious in identifying early signs of possible pacemaker failure, thus reducing the number of sudden pacemaker failures requiring emergency replacement. All systems that monitor the pacemaker rate (bpm) in both the free-running and/or magnetic mode are effective in detecting subclinical pacemaker failure due to battery depletion. More sophisticated systems are also capable of detecting internal electronic problems within the pulse generator itself and other potential problems. In the case of dual-chamber pacemakers in particular, such monitoring may detect failure of synchronization of the atria and ventricles, and the need for adjustment and reprogramming of the device.

NOTE: The transmitting device furnished to the patient is simply one component of the diagnostic system, and is not covered as durable medical equipment. Those engaged in transtelephonic pacemaker monitoring should reflect the costs of the transmitters in setting their charges for monitoring.

Indications and Limitations of Coverage

B. Definition of Transtelephonic Monitoring

In order for transtelephonic monitoring services to be covered, the services must consist of the following elements:

  • A minimum 30-second readable strip of the pacemaker in the free-running mode;
  • Unless contraindicated, a minimum 30-second readable strip of the pacemaker in the magnetic mode; and
  • A minimum 30 seconds of readable ECG strip.

C. Frequency Guidelines for Transtelephonic Monitoring

The guidelines below constitute a system which Medicare Administrative Contractors (MACs) should use, in conjunction with their knowledge of local medical practices, to screen claims for transtelephonic monitoring prior to payment. It is important to note that they are not recommendations with respect to a minimum frequency for such monitorings, but rather a maximum frequency (within which payment may be made without further claims development). As with previous guidelines, more frequent monitorings may be covered in cases where MACs are satisfied that such monitorings are medically necessary; e.g., based on the condition of the patient, or with respect to pacemakers exhibiting unexpected defects or premature failure. MACs should seek written justification for more frequent monitorings from the patient’s physician and/or any monitoring service involved.

These guidelines are divided into two broad categories - Guideline I which will apply to the majority of pacemakers now in use, and Guideline II which will apply only to pacemaker systems (pacemaker and leads) for which sufficient long-term clinical information exists to assure that they meet the standards of the Inter-Society Commission for Heart Disease Resources (ICHD) for longevity and end-of-life decay. (The ICHD standards are: (1) 90% cumulative survival at 5 years following implant; and (2) an end-of-life decay of less than a 50% drop of output voltage and less than 20% deviation of magnet rate, or a drop of 5 beats per minute or less, over a period of 3 months or more.) MACs should consult with their medical advisers and other appropriate individuals and organizations (such as the North American Society of Pacing and Electrophysiology which publishes product reliability information) should questions arise over whether a pacemaker system meets the ICHD standards.

The two groups of guidelines are then further broken down into two general categories – single-chamber and dual-chamber pacemakers. MACs should be aware that the frequency with which a patient is monitored may be changed from time-to-time for a number of reasons, such as a change in the patient’s overall condition, a reprogramming of the patient’s pacemaker, the development of better information on the pacemaker’s longevity or failure mode, etc. Consequently, changes in the proper set of guidelines may be required. MACs should inform physicians and monitoring services to alert MACs to any changes in the patient’s monitoring prescription that might necessitate changes in the screening guidelines applied to that patient. (Of particular importance is the reprogramming of a dual-chamber pacemaker to a single-chamber mode of operation. Such reprogramming would shift the patient from the appropriate dual-chamber guideline to the appropriate single-chamber guideline.)

Such reprogramming would shift the patient from the appropriate dual-chamber guideline to the appropriate single-chamber guideline.)

Guideline I

1 - Single-chamber pacemakers

1st month - every 2 weeks.
2nd through 36th month - every 8 weeks.
37th month to failure - every 4 weeks.
2 - Dual-chamber pacemaker
1st month - every 2 weeks.
2nd through 6th month - every 4 weeks.
7th through 36th month - every 8 weeks.
37th month to failure - every 4 weeks.

Guideline II

1 - Single-chamber pacemakers
1st month - every 2 weeks.
2nd through 48th month - every 12 weeks.
49th through 72nd month - every 8 weeks.
Thereafter - every 4 weeks.
2 - Dual-chamber pacemaker
1st month - every 2 weeks.
2nd through 30th month - every 12 weeks.
31st through 48th month - every 8 weeks.
Thereafter - every 4 weeks.

D. Pacemaker Clinic Services

1. General

Pacemaker monitoring is also covered when done by pacemaker clinics. Clinic visits may be done in conjunction with transtelephonic monitoring or as a separate service; however, the services rendered by a pacemaker clinic are more extensive than those currently possible by telephone. They include, for example, physical examination of patients and reprogramming of pacemakers. Thus, the use of one of these types of monitoring does not preclude concurrent use of the other.

2. Frequency Guidelines

As with transtelephonic pacemaker monitoring, the frequency of clinic visits is the decision of the patient’s physician, taking into account, among other things, the medical condition of the patient. However, MACs can develop monitoring guidelines that will prove useful in screening claims. The following are recommendations for monitoring guidelines on lithium-battery pacemakers:

  • For single-chamber pacemakers - twice in the first 6 months following implant, then once every 12 months.

  • For dual-chamber pacemakers - twice in the first 6 months, then once every 6 months.
Cross Reference
Claims Processing Instructions

Transmittal Information

Transmittal Number
Revision History
Other

National Coverage Analyses (NCAs)

This NCD has been or is currently being reviewed under the National Coverage Determination process. The following are existing associations with NCAs, from the National Coverage Analyses database.

Coding Analyses for Labs (CALs)

This NCD has been or is currently being reviewed under the National Coverage Determination process. The following are existing associations with CALs, from the Coding Analyses for Labs database.

Additional Information

Other Versions
Title Version Effective Between
Transtelephonic Monitoring of Cardiac Pacemakers 1 10/03/2003 - N/A You are here
CPT Copyright Statement
CPT only copyright 2002-2011 American Medical Association. All rights reserved. CPT is a registered trademark of the American Medical Association. Applicable FARS/DFARS Apply to Government Use. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein.
Reasons for Denial
Note: This section has not been negotiated by the Negotiated RuleMaking Committee. It includes CMS’s interpretation of it’s longstanding policies and is included for informational purposes. Tests for screening purposes that are performed in the absense of signs, symptoms, complaints, or personal history of disease or injury are not covered except as explicity authorized by statue. These include exams required by insurance companies, business establishments, government agencies, or other third parties. Tests that are not reasonable and necessary for the diagnosis or treatment of an illness or injury are not covered according to the statue. Failure to provide documentation of the medical necessity of tests may result in denial of claims. The documentation may include notes documenting relevant signs, symptoms, or abnormal findings that substantiate the medical necessity for ordering the tests. In addition, failure to provide independent verification that the test was ordered by the treating physician (or qualified nonphysician practitioner) through documentation in the physician’s office may result in denial. A claim for a test for which there is a national coverage or local medical review policy will be denied as not reasonable and necessary if it is submitted without an ICD-9-CM code or narrative diagnosis listed as covered in the policy unless other medical documentation justifying the necessity is submitted with the claim. If a national or local policy identifies a frequency expectation, a claim for a test that exceeds that expectation may be denied as not reasonable and necessary, unless it is submitted with documentation justifying increased frequency. Tests that are not ordered by a treating physician or other qualified treating nonphysician practitioner acting within the scope of their license and in compliance with Medicare requirements will be denied as not reasonable and necessary. Failure of the laboratory performing the test to have the appropriate Clinical Laboratory Improvement Act of 1988 (CLIA) certificate for the testing performed will result in denial of claims.